UBS Group
NXL icon

UBS Group’s Nexalin Technology NXL Stock Holding History

UBS Group’s Portfolio NXL Stock Details NXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.85K Buy
894
+154
+21% +$1.9K ﹤0.01% 8640
2026
Q1 		$7.72K Buy
740
+210
+40% +$3.28K ﹤0.01% 8558
2025
Q4 		$8.87K Buy
530
+515
+3,433% +$17.4K ﹤0.01% 8326
2025
Q3 		$403 Sell
15
-488
-97% -$13.8K ﹤0.01% 9693
2025
Q2 		$14.9K Buy
+503
New +$21.2K ﹤0.01% 8635
2025
Q1 		– Sell
-5
Closed -$386 – 10570
2024
Q4 		$386 Sell
5
-77
-94% -$6.43K ﹤0.01% 9493
2024
Q3 		$1.65K Sell
82
-53
-39% -$1.64K ﹤0.01% 8589
2024
Q2 		$6.82K Sell
135
-4
-3% -$176 ﹤0.01% 7885
2024
Q1 		$5.83K Buy
+139
New +$1.73K ﹤0.01% 7502
2023
Q3 		– Sell
-67
Closed -$1.79K – 9821
2023
Q2 		$1.79K Sell
67
-38
-36% -$960 ﹤0.01% 7854
2023
Q1 		$2.53K Sell
105
-42
-29% -$1.25K ﹤0.01% 8495
2022
Q4 		$3.3K Buy
147
+9
+7% +$414 ﹤0.01% 9529
2022
Q3 		$4K Buy
+138
New +$5.68K ﹤0.01% 9377

Other funds holding NXL

PEAK6
PEAK6 Chicago, Illinois $48.6B AUM 40.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

UBS Group's NXL Position: Q2 2026 in Review

UBS Group increased its Nexalin Technology (NXL) stake by 21% in Q2 2026, buying an estimated $1.9K and bringing the position to 894 shares worth $8.85K. The position accounts for ﹤0.01% of the portfolio, ranked #8640.

UBS Group first reported a position in NXL in Q3 2022 and has held it in 13 quarters since. The position peaked at $14.9K in Q2 2025. 20 funds tracked by Wall St. Rank hold NXL as of Q2 2026.

  • UBS Group held 894 shares of Nexalin Technology worth $8.85K as of Q2 2026.
  • UBS Group bought 154 Nexalin Technology shares in Q2 2026, an estimated $1.9K.
  • Nexalin Technology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8640 holding.
  • UBS Group first reported a position in Nexalin Technology in Q3 2022 and has held it in 13 quarters since.
  • UBS Group's Nexalin Technology position peaked at $14.9K in Q2 2025.
  • 20 funds tracked by Wall St. Rank held Nexalin Technology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.